XK
ENTA icon

Xact Kapitalforvaltning’s Enanta Pharmaceuticals ENTA Stock Holding History

Xact Kapitalforvaltning’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2,200
Closed -$210K – 1450
2019
Q1 		$210K Sell
2,200
-1,200
-35% -$108K ﹤0.01% 1375
2018
Q4 		$241K Buy
3,400
+900
+36% +$69K 0.01% 1355
2018
Q3 		$214K Hold
2,500
– – ﹤0.01% 1506
2018
Q2 		$290K Buy
+2,500
New +$249K 0.01% 1370

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Xact Kapitalforvaltning's ENTA Position: Q2 2019 in Review

Xact Kapitalforvaltning sold out of Enanta Pharmaceuticals (ENTA) in Q2 2019, closing a stake of 2,200 shares — an estimated $210K sold.

Xact Kapitalforvaltning first reported a position in ENTA in Q2 2018 and held it in 4 quarters. The position peaked at $290K in Q2 2018. 194 funds tracked by Wall St. Rank hold ENTA as of Q2 2019.

  • Xact Kapitalforvaltning reported no remaining Enanta Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Xact Kapitalforvaltning sold 2,200 Enanta Pharmaceuticals shares in Q2 2019, an estimated $210K.
  • Xact Kapitalforvaltning first reported a position in Enanta Pharmaceuticals in Q2 2018 and held it in 4 quarters.
  • Xact Kapitalforvaltning's Enanta Pharmaceuticals position peaked at $290K in Q2 2018.
  • 194 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2019.

Based on Xact Kapitalforvaltning's 13F filing for Q2 2019, filed 12 Jul 2019.